{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:56:59Z","timestamp":1794851819202,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K07927"],"award-info":[{"award-number":["22K07927"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ae0201004h0005"],"award-info":[{"award-number":["22ae0201004h0005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21ae0201004h0004"],"award-info":[{"award-number":["21ae0201004h0004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder characterized by an accumulation of glycosaminoglycans (GAGs), including heparan sulfate, in the body. Major manifestations involve the central nerve system (CNS), skeletal deformation, and visceral manifestations. About 30% of MPS II is linked with an attenuated type of disease subtype with visceral involvement. In contrast, 70% of MPS II is associated with a severe type of disease subtype with CNS manifestations that are caused by the human iduronate-2-sulfatase (<jats:italic>IDS<\/jats:italic>)-Pro86Leu (P86L) mutation, a common missense mutation in MPS II. In this study, we reported a novel <jats:italic>Ids<\/jats:italic>-P88L MPS II mouse model, an analogous mutation to human <jats:italic>IDS<\/jats:italic>-P86L. In this mouse model, a significant impairment of IDS enzyme activity in the blood with a short lifespan was observed. Consistently, the IDS enzyme activity of the body, as assessed in the liver, kidney, spleen, lung, and heart, was significantly impaired. Conversely, the level of GAG was elevated in the body. A putative biomarker with unestablished nature termed UA-HNAc(1S) (late retention time), one of two UA-HNAc(1S) species with late retention time on reversed-phase separation,is a recently reported MPS II-specific biomarker derived from heparan sulfate with uncharacterized mechanism. Thus, we asked whether this biomarker might be elevated in our mouse model. We found a significant accumulation of this biomarker in the liver, suggesting that hepatic formation could be predominant. Finally, to examine whether gene therapy could enhance IDS enzyme activity in this model, the efficacy of the nuclease-mediated genome correction system was tested. We found a marginal elevation of IDS enzyme activity in the treated group, raising the possibility that the effect of gene correction could be assessed in this mouse model. In conclusion, we established a novel <jats:italic>Ids<\/jats:italic>-P88L MPS II mouse model that consistently recapitulates the previously reported phenotype in several mouse models.<\/jats:p>","DOI":"10.1038\/s41598-023-34541-w","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:03:39Z","timestamp":1684163019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation"],"prefix":"10.1038","volume":"13","author":[{"given":"Ryuichi","family":"Mashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"34541_CR1","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer, J. Overview of the mucopolysaccharidoses. Rheumatology 50, v4\u2013v12. https:\/\/doi.org\/10.1093\/rheumatology\/ker394 (2011).","journal-title":"Rheumatology"},{"key":"34541_CR2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"SA Jones","year":"2009","unstructured":"Jones, S. A. et al. Mortality and cause of death in mucopolysaccharidosis type II\u2014a historical review based on data from the Hunter Outcome Survey (HOS). J. Inherit. Metab. Dis. 32, 534\u2013543. https:\/\/doi.org\/10.1007\/s10545-009-1119-7 (2009).","journal-title":"J. Inherit. Metab. Dis."},{"key":"34541_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. Prevalence of lysosomal storage disorders. JAMA 281, 249\u2013254 (1999).","journal-title":"JAMA"},{"key":"34541_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0635-z","author":"J Muenzer","year":"2017","unstructured":"Muenzer, J. et al. Ten years of the Hunter Outcome Survey (HOS): Insights, achievements, and lessons learned from a global patient registry. J. Rare Dis. https:\/\/doi.org\/10.1186\/s13023-017-0635-z (2017).","journal-title":"J. Rare Dis."},{"key":"34541_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","volume":"29","author":"T Okuyama","year":"2021","unstructured":"Okuyama, T. et al. A phase 2\/3 trial of pabinafusp alfa IDS Fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol. Ther. 29, 671\u2013679. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.039 (2021).","journal-title":"Mol. Ther."},{"key":"34541_CR6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","volume":"26","author":"H Sonoda","year":"2018","unstructured":"Sonoda, H. et al. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol. Ther. 26, 1366\u20131374. https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.032 (2018).","journal-title":"Mol. Ther."},{"key":"34541_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/gim.2015.36","volume":"18","author":"J Muenzer","year":"2016","unstructured":"Muenzer, J. et al. A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet. Med. 18, 73\u201381. https:\/\/doi.org\/10.1038\/gim.2015.36 (2016).","journal-title":"Genet. Med."},{"key":"34541_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.05.003","author":"M Kosuga","year":"2016","unstructured":"Kosuga, M. et al. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase. Mol. Genet. Metab. https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.003 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"34541_CR9","doi-asserted-by":"publisher","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","volume":"127","author":"JB Holt","year":"2011","unstructured":"Holt, J. B., Poe, M. D. & Escolar, M. L. Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics 127, e1258\u2013e1265. https:\/\/doi.org\/10.1542\/peds.2010-1274 (2011).","journal-title":"Pediatrics"},{"key":"34541_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/GLYCOB\/CWH049","volume":"14","author":"M Fuller","year":"2004","unstructured":"Fuller, M., Meikle, P. J. & Hopwood, J. J. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology 14, 443\u2013450. https:\/\/doi.org\/10.1093\/GLYCOB\/CWH049 (2004).","journal-title":"Glycobiology"},{"key":"34541_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/J.AB.2010.04.002","volume":"402","author":"TC Nielsen","year":"2010","unstructured":"Nielsen, T. C., Rozek, T., Hopwood, J. J. & Fuller, M. Determination of urinary oligosaccharides by high-performance liquid chromatography\/electrospray ionization-tandem mass spectrometry: Application to Hunter syndrome. Anal. Biochem. 402, 113\u2013120. https:\/\/doi.org\/10.1016\/J.AB.2010.04.002 (2010).","journal-title":"Anal. Biochem."},{"key":"34541_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41436-018-0136-z","volume":"21","author":"JT Saville","year":"2019","unstructured":"Saville, J. T., McDermott, B. K., Fletcher, J. M. & Fuller, M. Disease and subtype specific signatures enable precise diagnosis of the mucopolysaccharidoses. Genet Med. 21, 753\u2013757. https:\/\/doi.org\/10.1038\/s41436-018-0136-z (2019).","journal-title":"Genet Med."},{"key":"34541_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/IJNS6030069","volume":"6","author":"ZM Herbst","year":"2020","unstructured":"Herbst, Z. M., Urdaneta, L., Klein, T., Fuller, M. & Gelb, M. H. Evaluation of multiple methods for quantification of glycosaminoglycan biomarkers in newborn dried blood spots from patients with severe and attenuated mucopolysaccharidosis-I. Int. J. Neonatal. Screen 6, 69. https:\/\/doi.org\/10.3390\/IJNS6030069 (2020).","journal-title":"Int. J. Neonatal. Screen"},{"key":"34541_CR14","doi-asserted-by":"publisher","first-page":"15786","DOI":"10.1038\/ncomms15786","volume":"8","author":"M Demydchuk","year":"2017","unstructured":"Demydchuk, M. et al. Insights into Hunter syndrome from the structure of iduronate-2-sulfatase. Nat. Commun. 8, 15786. https:\/\/doi.org\/10.1038\/ncomms15786 (2017).","journal-title":"Nat. Commun."},{"key":"34541_CR15","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/J.BBAMCR.2008.11.015","volume":"1793","author":"T Dierks","year":"2009","unstructured":"Dierks, T. et al. Molecular basis of multiple sulfatase deficiency, mucolipidosis II\/III and Niemann-Pick C1 disease-Lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim. Biophys. Acta 1793, 710\u2013725. https:\/\/doi.org\/10.1016\/J.BBAMCR.2008.11.015 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"34541_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s10545-007-0641-8","volume":"30","author":"AR Garcia","year":"2007","unstructured":"Garcia, A. R., Pan, J., Lamsa, J. C. & Muenzer, J. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J. Inherit. Metab. Dis. 30, 924\u2013934. https:\/\/doi.org\/10.1007\/s10545-007-0641-8 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"key":"34541_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3349\/YMJ.2011.52.2.263","volume":"52","author":"JH Lee","year":"2011","unstructured":"Lee, J. H., Choe, Y. H., Kim, S. J., Paik, K. H. & Jin, D. K. Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation. Yonsei Med. J. 52, 263\u2013267. https:\/\/doi.org\/10.3349\/YMJ.2011.52.2.263 (2011).","journal-title":"Yonsei Med. J."},{"key":"34541_CR18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","volume":"27","author":"T Okuyama","year":"2019","unstructured":"Okuyama, T. et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: A phase 1\/2 trial. Mol. Ther. 27, 456\u2013464. https:\/\/doi.org\/10.1016\/j.ymthe.2018.12.005 (2019).","journal-title":"Mol. Ther."},{"key":"34541_CR19","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1093\/HMG\/DDI351","volume":"14","author":"M Sardiello","year":"2005","unstructured":"Sardiello, M., Annunziata, I., Roma, G. & Ballabio, A. Sulfatases and sulfatase modifying factors: An exclusive and promiscuous relationship. Hum. Mol. Genet. 14, 3203\u20133217. https:\/\/doi.org\/10.1093\/HMG\/DDI351 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"34541_CR20","doi-asserted-by":"publisher","first-page":"14900","DOI":"10.1074\/JBC.M413383200","volume":"280","author":"A Preusser-Kunze","year":"2005","unstructured":"Preusser-Kunze, A. et al. Molecular characterization of the human Calpha-formylglycine-generating enzyme. J. Biol. Chem. 280, 14900\u201314910. https:\/\/doi.org\/10.1074\/JBC.M413383200 (2005).","journal-title":"J. Biol. Chem."},{"key":"34541_CR21","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1038\/srep05396","volume":"4","author":"M Inui","year":"2014","unstructured":"Inui, M. et al. Rapid generation of mouse models with defined point mutations by the CRISPR\/Cas9 system. Sci. Rep. 4, 5396. https:\/\/doi.org\/10.1038\/srep05396 (2014).","journal-title":"Sci. Rep."},{"key":"34541_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2022.03.045","author":"A Raguram","year":"2022","unstructured":"Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell https:\/\/doi.org\/10.1016\/J.CELL.2022.03.045 (2022).","journal-title":"Cell"},{"key":"34541_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/NBT.2884","volume":"32","author":"H Yin","year":"2014","unstructured":"Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551\u2013553. https:\/\/doi.org\/10.1038\/NBT.2884 (2014).","journal-title":"Nat. Biotechnol."},{"key":"34541_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/NBT.3471","volume":"34","author":"H Yin","year":"2016","unstructured":"Yin, H. et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34, 328\u2013333. https:\/\/doi.org\/10.1038\/NBT.3471 (2016).","journal-title":"Nat. Biotechnol."},{"key":"34541_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/ADMA.202006619","author":"L Farbiak","year":"2021","unstructured":"Farbiak, L. et al. All-in-one dendrimer-based lipid nanoparticles enable precise HDR-mediated gene editing in vivo. Adv. Mater. https:\/\/doi.org\/10.1002\/ADMA.202006619 (2021).","journal-title":"Adv. Mater."},{"key":"34541_CR26","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/J.YMTHE.2018.03.002","volume":"26","author":"K Laoharawee","year":"2018","unstructured":"Laoharawee, K. et al. Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing. Mol. Ther. 26, 1127\u20131136. https:\/\/doi.org\/10.1016\/J.YMTHE.2018.03.002 (2018).","journal-title":"Mol. Ther."},{"key":"34541_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1089\/HUM.2016.184","volume":"28","author":"K Laoharawee","year":"2017","unstructured":"Laoharawee, K. et al. Prevention of neurocognitive deficiency in mucopolysaccharidosis type II mice by central nervous system-directed, AAV9-mediated iduronate sulfatase gene transfer. Hum. Gene Ther. 28, 626\u2013638. https:\/\/doi.org\/10.1089\/HUM.2016.184 (2017).","journal-title":"Hum. Gene Ther."},{"key":"34541_CR28","doi-asserted-by":"publisher","first-page":"e86696","DOI":"10.1172\/jci.insight.86696","volume":"1","author":"S Motas","year":"2016","unstructured":"Motas, S. et al. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight 1, e86696. https:\/\/doi.org\/10.1172\/jci.insight.86696 (2016).","journal-title":"JCI Insight"},{"key":"34541_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.GIM.2022.04.002","author":"J Muenzer","year":"2022","unstructured":"Muenzer, J. et al. Long-term open-label phase I\/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II. Genet. Med. https:\/\/doi.org\/10.1016\/J.GIM.2022.04.002 (2022).","journal-title":"Genet. Med."},{"key":"34541_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS23041963","author":"R Mashima","year":"2022","unstructured":"Mashima, R., Okuyama, T. & Ohira, M. Physiology and pathophysiology of heparan sulfate in animal models: Its biosynthesis and degradation. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/IJMS23041963 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"34541_CR31","doi-asserted-by":"publisher","first-page":"D571","DOI":"10.1093\/NAR\/GKAB1045","volume":"50","author":"E Drula","year":"2022","unstructured":"Drula, E. et al. The carbohydrate-active enzyme database: Functions and literature. Nucleic Acids Res. 50, D571\u2013D577. https:\/\/doi.org\/10.1093\/NAR\/GKAB1045 (2022).","journal-title":"Nucleic Acids Res."},{"key":"34541_CR32","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.1073\/PNAS.1704367114","volume":"114","author":"A Cartmell","year":"2017","unstructured":"Cartmell, A. et al. How members of the human gut microbiota overcome the sulfation problem posed by glycosaminoglycans. Proc. Natl. Acad. Sci. USA 114, 7037\u20137042. https:\/\/doi.org\/10.1073\/PNAS.1704367114 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"34541_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/S41586-021-03967-5","volume":"598","author":"AS Luis","year":"2021","unstructured":"Luis, A. S. et al. A single sulfatase is required to access colonic mucin by a gut bacterium. Nature 598, 332\u2013337. https:\/\/doi.org\/10.1038\/S41586-021-03967-5 (2021).","journal-title":"Nature"},{"key":"34541_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/S41589-022-01039-X","author":"AS Luis","year":"2022","unstructured":"Luis, A. S. et al. Sulfated glycan recognition by carbohydrate sulfatases of the human gut microbiota. Nat. Chem. Biol. https:\/\/doi.org\/10.1038\/S41589-022-01039-X (2022).","journal-title":"Nat. Chem. Biol."},{"key":"34541_CR35","doi-asserted-by":"publisher","first-page":"34019","DOI":"10.1074\/JBC.M109.025338","volume":"284","author":"YH Han","year":"2009","unstructured":"Han, Y. H. et al. Structural snapshots of heparin depolymerization by heparin lyase I. J. Biol. Chem. 284, 34019\u201334027. https:\/\/doi.org\/10.1074\/JBC.M109.025338 (2009).","journal-title":"J. Biol. Chem."},{"key":"34541_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-020-14509-4","author":"D Ndeh","year":"2020","unstructured":"Ndeh, D. et al. Metabolism of multiple glycosaminoglycans by Bacteroides thetaiotaomicron is orchestrated by a versatile core genetic locus. Nat. Commun. https:\/\/doi.org\/10.1038\/S41467-020-14509-4 (2020).","journal-title":"Nat. Commun."},{"key":"34541_CR37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/J.CHOM.2022.02.001","volume":"30","author":"NA Pudlo","year":"2022","unstructured":"Pudlo, N. A. et al. Diverse events have transferred genes for edible seaweed digestion from marine to human gut bacteria. Cell Host Microbe 30, 314-328.e11. https:\/\/doi.org\/10.1016\/J.CHOM.2022.02.001 (2022).","journal-title":"Cell Host Microbe"},{"key":"34541_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/S41579-022-00712-1","author":"JF Wardman","year":"2022","unstructured":"Wardman, J. F., Bains, R. K., Rahfeld, P. & Withers, S. G. Carbohydrate-active enzymes (CAZymes) in the gut microbiome. Nat. Rev. Microbiol. https:\/\/doi.org\/10.1038\/S41579-022-00712-1 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"34541_CR39","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/AJCN\/39.2.338","volume":"39","author":"NI McNeil","year":"1984","unstructured":"McNeil, N. I. The contribution of the large intestine to energy supplies in man. Am. J. Clin. Nutr. 39, 338\u2013342. https:\/\/doi.org\/10.1093\/AJCN\/39.2.338 (1984).","journal-title":"Am. J. Clin. Nutr."},{"key":"34541_CR40","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ymgme.2011.09.002","volume":"104","author":"E Oda","year":"2011","unstructured":"Oda, E. et al. Newborn screening for Pompe disease in Japan. Mol. Genet. Metab. 104, 560\u2013565. https:\/\/doi.org\/10.1016\/j.ymgme.2011.09.002 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"34541_CR41","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/clinchem\/35.7.1472","volume":"35","author":"JGN de Jong","year":"1989","unstructured":"de Jong, J. G. N., Wevers, R. A., Laarakkers, C. & Poorthuis, B. J. H. M. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: A rapid screening procedure for mucopolysaccharidoses. Clin. Chem. 35, 1472\u20131477. https:\/\/doi.org\/10.1093\/clinchem\/35.7.1472 (1989).","journal-title":"Clin. Chem."},{"key":"34541_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2016.03.009","author":"R Mashima","year":"2016","unstructured":"Mashima, R., Sakai, E., Tanaka, M., Kosuga, M. & Okuyama, T. The levels of urinary glycosaminoglycans of patients with attenuated and severe type of mucopolysaccharidosis II determined by liquid chromatography-tandem mass spectrometry. Mol. Genet. Metab. Rep. https:\/\/doi.org\/10.1016\/j.ymgmr.2016.03.009 (2016).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"34541_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2017.12.001","author":"R Mashima","year":"2018","unstructured":"Mashima, R., Ohira, M., Okuyama, T. & Tatsumi, A. Quantification of the enzyme activities of iduronate-2-sulfatase, N-acetylgalactosamine-6-sulfatase and N-acetylgalactosamine-4-sulfatase using liquid chromatography-tandem mass spectrometry. Mol. Genet. Metab. Rep. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.12.001 (2018).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"34541_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ymgmr.2018.08.005","volume":"17","author":"M Ohira","year":"2018","unstructured":"Ohira, M., Okuyama, T. & Mashima, R. Quantification of 11 enzyme activities of lysosomal storage disorders using liquid chromatography-tandem mass spectrometry. Mol. Genet. Metab. Rep. 17, 9\u201315. https:\/\/doi.org\/10.1016\/j.ymgmr.2018.08.005 (2018).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"34541_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/IJNS8010009","author":"ZM Herbst","year":"2022","unstructured":"Herbst, Z. M. et al. Evaluation of two methods for quantification of glycosaminoglycan biomarkers in newborn dried blood spots from patients with severe and attenuated mucopolysaccharidosis Type II. Int. J. Neonatal. Screen https:\/\/doi.org\/10.3390\/IJNS8010009 (2022).","journal-title":"Int. J. Neonatal. Screen"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34541-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34541-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34541-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:20:04Z","timestamp":1684164004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34541-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["34541"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-34541-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"6 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7865"}}